Colorectal Cancer Alliance

New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Health Technology, Health, Oncology, Anxiety, Education, Colorectal cancer, Colonoscopy, Physician, FDA, Pain, Gastroenterology, Colorectal Cancer Alliance, CRC, Perception, Survival rate, Fear, Patient, The Harris Poll, Helmy Eltoukhy, Cancer, Online shopping

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option.
  • The survey polled 1,000 American adults age 45-84, along with 351 physicians (250 primary care providers and 101 gastroenterologists).
  • In the United States, CRC screening guidelines recommend that all people of average risk begin screening starting at age 45.
  • Ultimately, 96% of all physicians surveyed would recommend an FDA-approved blood test to their patients for CRC screening.

Olympus and the Colorectal Cancer Alliance Offer a Reminder About the Importance of Preventive Cancer Screenings

Retrieved on: 
Tuesday, March 5, 2024
Large intestine, PCP, Incidence, American Cancer Society, Woman, Texture, Gastroenterology, Colorectal cancer, Colonoscopy, TXI, Physician, Extrapyramidal system, ADR, Polyp, Colorectal Cancer Alliance, CRC, FIT, Learning, Risk, Adenoma, Health, History, USPSTF, Cancer, Patient, Diagnosis, CCA, Medical imaging

CENTER VALLEY, Pa., March 5, 2024 /PRNewswire/ -- As the American Cancer Society reports an increase in death rates from colorectal cancer for patients under the age of 50,1 Olympus Corporation of the Americas and the Colorectal Cancer Alliance (CCA) offer a reminder about the importance of preventive screenings and knowing your family health history.

Key Points: 
  • CENTER VALLEY, Pa., March 5, 2024 /PRNewswire/ -- As the American Cancer Society reports an increase in death rates from colorectal cancer for patients under the age of 50,1 Olympus Corporation of the Americas and the Colorectal Cancer Alliance (CCA) offer a reminder about the importance of preventive screenings and knowing your family health history.
  • More than 20 years ago, colorectal cancer (CRC) was known to be the fourth-leading cause of cancer death in men and women under the age of 50, according to the American Cancer Society.
  • Now, CRC is the leading cause of cancer death for men under the age of 50 and the second leading cause for women under 50.
  • Colorectal cancer is preventable, and the power to prevent it rests in your hands."

With Colorectal Cancer Rates Rising, the American Cancer Society and Colorectal Cancer Alliance Join Forces to Increase Screening

Retrieved on: 
Thursday, February 29, 2024
Large intestine, Ulcerative colitis, Incidence, American Cancer Society, Woman, Crohn's disease, Diet, Colorectal cancer, Smoking, Cancer, ACS, Hereditary nonpolyposis colorectal cancer, Weight loss, Polyp, Colorectal Cancer Alliance, Exercise, Calcium, Meat, Risk, Weakness, Survival rate, Alaska Natives, Vegetable, Rectum, USPSTF, Fatigue, Chronic pain, Death, Black, Locator, Ageing, Dairy

ATLANTA, Feb. 29, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.

Key Points: 
  • ATLANTA, Feb. 29, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.
  • According to the American Cancer Society's Cancer Fact & Figures, 2024 report , colorectal cancer is now the leading cause of cancer death in men and the second in women under 50 years old.
  • "By joining forces with the Colorectal Cancer Alliance, we can reach more individuals and empower them with vital information that can save lives."
  • Matching an American Cancer Society 2018 update to colorectal cancer screening guidelines , and the Alliance's call for earlier screening, the United States Preventive Services Task Force (USPSTF) released a recommendation statement lowering the age to begin colorectal cancer screening from age 50 to age 45 in 2021.

Dak Prescott Joins Ryan Reynolds’ Maximum Effort and the Colorectal Cancer Alliance to ‘LEAD FROM BEHIND’

Retrieved on: 
Friday, December 8, 2023
Oncology, Philanthropy, Entertainment, Health, Celebrity, Other Philanthropy, Other Health, Research, Prevent Cancer Foundation, DNA, Exact Sciences (company), Colorectal cancer, Love, Risk, Disease, Colorectal Cancer Alliance, Multimedia, Patient, NFL, Exact sciences, Blood, Health equity, FIT, Cancer, Diagnosis, Survival, Geography, Poverty, Partnership, Dallas Cowboys, Sport, Colonoscopy, Dairy, Birth control, Pharmaceutical industry, Black

NFL quarterback Dak Prescott of the Dallas Cowboys is teaming up with the nation’s leading nonprofit dedicated to colon cancer, the Colorectal Cancer Alliance (Alliance), and Ryan Reynolds’ creative agency, Maximum Effort, to LEAD FROM BEHIND.

Key Points: 
  • NFL quarterback Dak Prescott of the Dallas Cowboys is teaming up with the nation’s leading nonprofit dedicated to colon cancer, the Colorectal Cancer Alliance (Alliance), and Ryan Reynolds’ creative agency, Maximum Effort, to LEAD FROM BEHIND.
  • “Losing my mother to colon cancer was devastating, and no one should have to go through that,” said Prescott.
  • “I’d like to thank Dak for joining Rob McElhenney, Terry Crews, and me in helping raise awareness for dropping your drawers,” said Maximum Effort Co-founder Ryan Reynolds.
  • "The mission of the Alliance is to end colorectal cancer in our lifetime,” said Michael Sapienza, CEO of the Colorectal Cancer Alliance.

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Retrieved on: 
Wednesday, November 8, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Survival, VEGF, TAK, RAS, PDUFA, Food, Colorectal Cancer Alliance, MAA, Priority, JAMA, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medicines and Healthcare products Regulatory Agency, Priority review, PMDA, Colorectal cancer, CRC, EMA, FACP, Cancer, Metastasis, Patient, Diagnosis, Vanderbilt University Medical Center, Pharmaceutical industry, Takeda, EU, Lancet

"There is a pressing need for new treatments for individuals with metastatic colorectal cancer, who have had limited options and continue to face poor outcomes.

Key Points: 
  • "There is a pressing need for new treatments for individuals with metastatic colorectal cancer, who have had limited options and continue to face poor outcomes.
  • “For far too long, healthcare providers and patients have had limited options when selecting a therapy for metastatic colorectal cancer.
  • The trials investigated FRUZAQLA plus best supportive care versus placebo plus best supportive care in patients with previously treated mCRC.
  • “Colorectal cancer is a highly heterogeneous disease, making it difficult to bring advancements to patients whose cancer has metastasized.

Independence Blue Cross and The Colorectal Cancer Alliance Launch 45+ Reasons Campaign to Support Colorectal Cancer Prevention

Retrieved on: 
Tuesday, August 8, 2023
Survival rate, Independence Blue Cross, Perelman School of Medicine at the University of Pennsylvania, Partnership, University, Wellness, Health equity, Cancer, Large intestine, African Americans, Colorectal Cancer Alliance, Penn Medicine Rittenhouse, Black, Organization, Perelman Center for Advanced Medicine, Community Alliance, Incidence, Colorectal cancer, Development, MD, Pennsylvania Department of Aging, Risk, Salix Pharmaceuticals, Child, Colonoscopy, Cycle, Diversity, Radio, University of Pennsylvania Health System, Mortality, American Cancer Society, USPSTF, Willow, Pennsylvania Department of Health, Social media, Disease, Pharmaceutical industry, Mobile phone, Vaccine, Independence, Medicine

PHILADELPHIA, Aug. 8, 2023 /PRNewswire/ -- Independence Blue Cross (Independence) and the Colorectal Cancer Alliance (the Alliance) announced the launch of 45+ Reasons, a campaign to get more than 5,000 Black Philadelphians ages 45-75 screened for colorectal cancer to reduce the significantly higher incidence and mortality rates of Black Americans. The campaign supports the Cycles of Impact initiative launched by Independence and the Alliance in 2022.

Key Points: 
  • To ensure that the colorectal cancer prevention and screening messages reach those most at risk, the Alliance is launching a compelling new awareness campaign called 45+ Reasons.
  • The community engagement, social media, and advertising campaign aims to instill much-needed trust in the healthcare system with fact-based support for colorectal cancer as a preventable cancer.
  • One way we are addressing this is through this partnership with the Colorectal Cancer Alliance to reduce gaps in colorectal cancer screening rates among Black Philadelphians, who are disproportionately impacted by colorectal cancer."
  • "As the largest nonprofit organization solely committed to ending colorectal cancer, the Alliance is uniquely positioned to lead this bold health intervention," said Michael Sapienza, CEO of the Colorectal Cancer Alliance.

Terry Crews and His Creative Company Super Serious Join Ryan Reynolds’ Maximum Effort and the Colorectal Cancer Alliance to ‘LEAD FROM BEHIND’

Retrieved on: 
Tuesday, July 25, 2023
Oncology, Philanthropy, Health, Other Health, Other Philanthropy, Foundation, Survival rate, Idiocracy, NFL, DNA, Prevent Cancer Foundation, FIT, Cancer, Woman, Crew, Risk, Antibody, Colorectal Cancer Alliance, African Americans, Colon, CDC, Incidence, Love, Blood, Colonoscopy, Colorectal cancer, Sport, The Super Serious Show, Mortality, Exact Sciences (company), Polyp, Disease, Mobile phone, Birth control, Video game

The nation’s leading nonprofit dedicated to colon cancer, the Colorectal Cancer Alliance (Alliance) is reteaming with Ryan Reynolds’ creative agency, Maximum Effort, to reignite LEAD FROM BEHIND, featuring Terry Crews to kick-off the effort.

Key Points: 
  • The nation’s leading nonprofit dedicated to colon cancer, the Colorectal Cancer Alliance (Alliance) is reteaming with Ryan Reynolds’ creative agency, Maximum Effort, to reignite LEAD FROM BEHIND, featuring Terry Crews to kick-off the effort.
  • Colon cancer is the second deadliest cancer in the U.S., yet it is highly preventable with timely screening.
  • “I’ve partnered with the Colorectal Cancer Alliance and LEAD FROM BEHIND because together we can prevent unnecessary suffering from The Preventable Cancer,” said Terry Crews.
  • That’s why colon cancer is The Preventable Cancer,” said Michael Sapienza, CEO of the Colorectal Cancer Alliance.

 U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in Combination With Cetuximab to Identify Patients With BRAF V600E Alterations in Metastatic Colorectal Cancer

Retrieved on: 
Friday, June 9, 2023
Science, Biometrics, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, CGP, Encorafenib, BRAF, Woman, Large intestine, NSCLC, Lung cancer, Doctor of Philosophy, Cetuximab, Colorectal cancer, MD, Patient, Liquid, Foundation Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Colorectal Cancer Alliance, Food, Breast cancer, Pharmaceutical industry

This now makes FoundationOne Liquid CDx the only comprehensive genomic profiling (CGP) test FDA-approved to identify patients with BRAF V600E alterations in mCRC who may be appropriate for treatment with BRAFTOVI in combination with cetuximab.

Key Points: 
  • This now makes FoundationOne Liquid CDx the only comprehensive genomic profiling (CGP) test FDA-approved to identify patients with BRAF V600E alterations in mCRC who may be appropriate for treatment with BRAFTOVI in combination with cetuximab.
  • Colorectal cancer is one of the most common and deadly cancers globally.1BRAF V600E alterations are estimated to occur in approximately 8% of patients with metastatic CRC.2 Historically, there have been limited treatment options available, so patients with this condition generally face a poor prognosis.
  • The test has several companion diagnostic indications across non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, plus a pan tumor indication specific to NTRK1/2/3 fusions.
  • “We’re encouraged by the ongoing progress happening in colorectal cancer care, and believe this approval is an important milestone in delivering broader access to more treatment options.”

Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test

Retrieved on: 
Tuesday, May 9, 2023
Oncology, Health, Medical Devices, Health Technology, General Health, Research, Science, DNA, ECLIPSE, CRC, Shield, Clinical trial, Cancer, Large intestine, Colorectal Cancer Alliance, GH, Harvard Medical School, DDW, Colorectal cancer, Helmy Eltoukhy, MD, Guideline, Patient, Evaluation, Study, Hospital, Neoplasm, Massachusetts General Hospital, Abstract, Death, Medical imaging, Birth control, Medicine

The ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode) study is an over 20,000 patient registrational study evaluating the performance of the Shield blood test for detecting CRC in average-risk adults.

Key Points: 
  • The ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode) study is an over 20,000 patient registrational study evaluating the performance of the Shield blood test for detecting CRC in average-risk adults.
  • The data presented at DDW elaborates on the top-line data the company announced in December 2022.
  • Blood tests have the potential to change that,” said Michael Sapienza, chief executive officer of the Colorectal Cancer Alliance.
  • The Shield test is spearheading a new patient-preferred category in CRC screening and has the potential to significantly increase overall screening rates,” said AmirAli Talasaz, Guardant Health co-CEO.

Envision Healthcare’s 2022 Clinical Impact Report Illustrates the Many Ways Teams Cared for and Positively Impacted Millions of People

Retrieved on: 
Thursday, April 27, 2023
Radiology, Managed Care, Surgery, Oncology, General Health, Health, Hospitals, Other Health, The Prince of Wales's Charitable Fund, Medicaid, Education, White stork, Centers for Medicare & Medicaid Services, Hurricane Ian, Research, Envision Healthcare, Equity, Colorectal Cancer Alliance, Hygiene, Medicare, Dominican Republic, Publication, Patient, Physician, Colorectal cancer, Inclusion, Perioperative medicine, Research institute, ET3, United Way, Organic, H. Lee Moffitt Cancer Center & Research Institute, Pharmaceutical industry, Nursing, Envision

In 2022, Envision clinicians continued outperforming national quality benchmarks while treating complex medical conditions and authoring two Centers for Medicare & Medicaid Services-approved national clinical quality measures.

Key Points: 
  • In 2022, Envision clinicians continued outperforming national quality benchmarks while treating complex medical conditions and authoring two Centers for Medicare & Medicaid Services-approved national clinical quality measures.
  • Through programs like Emergency Triage, Treat and Transport (ET3), Envision teams provided patients the right care at the right time and in the right place.
  • In 2022, Envision redefined its organizational structure to build a transformative care experience for patients and drive clinical innovation.
  • As part of their passion for improving healthcare worldwide, Envision clinicians and clinical support teammates cared for communities in need through Envision’s Global Health Initiative.